Karyopharm Therapeutics | KPTI - أصول متداولة





أصول متداولة تغيير تاريخ
AbbVie USD 29.06B 523M 2025-12
Abbott USD 26B 1.16B 2025-12
Amgen USD 29.06B 1.17B 2025-12
AstraZeneca USD 28.72B 1.22B 2025-12
BioCryst Pharmaceuticals USD 404.35M 48.66M 2025-12
Bristol-Myers Squibb USD 35.63B 2.41B 2025-09
Eli Lilly USD 55.63B 6.44B 2025-12
Enanta Pharmaceuticals USD 198.68M 5.65M 2025-12
GlaxoSmithKline GBP 17.51B 332M 2025-12
Incyte USD 5.02B 746.01M 2025-12
J&J USD 55.62B 1.01B 2025-12
Karyopharm Therapeutics USD 89.75M 8.12M 2025-09
MacroGenics USD 219.94M 12.15M 2025-12
Merck USD 47.56B 10.49B 2025-09
Nektar Therapeutics USD 281.36M 94.79M 2025-09
Novartis USD 30.46B 2.26B 2025-12
Novartis USD 30.46B 2.26B 2025-12
Pfizer USD 46.92B 3.22B 2025-09
Regeneron Pharmaceuticals USD 18.02B 41.2M 2025-12
Roche Holding CHF 38.73B 3.03B 2025-12
Sangamo BioSciences USD 49.89M 12.3M 2025-06
Takeda JPY 3.12T 195.82B 2025-12
Tectonic Therapeutic USD 257.36M 15.88M 2025-12
TG Therapeutics USD 630.76M 31M 2025-12
Ultragenyx Pharmaceutical USD 643.21M 76.58M 2025-09
Xencor USD 599.82M 81.38M 2025-12